Bioengineering of air-filled protein nanoparticles by genetic and chemical functionalization.
Bioengineering
Biomaterials
Extremophiles
Gas vesicle
Halophiles
Nanoparticles
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
25 Mar 2023
25 Mar 2023
Historique:
received:
29
01
2023
accepted:
20
03
2023
medline:
28
3
2023
entrez:
25
3
2023
pubmed:
26
3
2023
Statut:
epublish
Résumé
Various bacteria and archaea, including halophilic archaeon Halobacterium sp. NRC-1 produce gas vesicle nanoparticles (GVNPs), a unique class of stable, air-filled intracellular proteinaceous nanostructures. GVNPs are an attractive tool for biotechnological applications due to their readily production, purification, and unique physical properties. GVNPs are spindle- or cylinder-shaped, typically with a length of 100 nm to 1.5 μm and a width of 30-250 nm. Multiple monomeric subunits of GvpA and GvpC proteins form the GVNP shell, and several additional proteins are required as minor structural or assembly proteins. The haloarchaeal genetic system has been successfully used to produce and bioengineer GVNPs by fusing several foreign proteins with GvpC and has shown various applications, such as biocatalysis, diagnostics, bioimaging, drug delivery, and vaccine development. We demonstrated that native GvpC can be removed in a low salt buffer during the GVNP purification, leaving the GvpA-based GVNP's shell intact and stable under physiological conditions. Here, we report a genetic engineering and chemical modification approach for functionalizing the major GVNP protein, GvpA. This novel approach is based on combinatorial cysteine mutagenesis within GvpA and genetic expansion of the N-terminal and C-terminal regions. Consequently, we generated GvpA single, double, and triple cysteine variant libraries and investigated the impact of mutations on the structure and physical shape of the GVNPs formed. We used a thiol-maleimide chemistry strategy to introduce the biotechnological relevant activity by maleimide-activated streptavidin-biotin and maleimide-activated SpyTag003-SpyCatcher003 mediated functionalization of GVNPs. The merger of these genetic and chemical functionalization approaches significantly extends these novel protein nanomaterials' bioengineering and functionalization potential to assemble catalytically active proteins, biomaterials, and vaccines onto one nanoparticle in a modular fashion.
Sections du résumé
BACKGROUND
BACKGROUND
Various bacteria and archaea, including halophilic archaeon Halobacterium sp. NRC-1 produce gas vesicle nanoparticles (GVNPs), a unique class of stable, air-filled intracellular proteinaceous nanostructures. GVNPs are an attractive tool for biotechnological applications due to their readily production, purification, and unique physical properties. GVNPs are spindle- or cylinder-shaped, typically with a length of 100 nm to 1.5 μm and a width of 30-250 nm. Multiple monomeric subunits of GvpA and GvpC proteins form the GVNP shell, and several additional proteins are required as minor structural or assembly proteins. The haloarchaeal genetic system has been successfully used to produce and bioengineer GVNPs by fusing several foreign proteins with GvpC and has shown various applications, such as biocatalysis, diagnostics, bioimaging, drug delivery, and vaccine development.
RESULTS
RESULTS
We demonstrated that native GvpC can be removed in a low salt buffer during the GVNP purification, leaving the GvpA-based GVNP's shell intact and stable under physiological conditions. Here, we report a genetic engineering and chemical modification approach for functionalizing the major GVNP protein, GvpA. This novel approach is based on combinatorial cysteine mutagenesis within GvpA and genetic expansion of the N-terminal and C-terminal regions. Consequently, we generated GvpA single, double, and triple cysteine variant libraries and investigated the impact of mutations on the structure and physical shape of the GVNPs formed. We used a thiol-maleimide chemistry strategy to introduce the biotechnological relevant activity by maleimide-activated streptavidin-biotin and maleimide-activated SpyTag003-SpyCatcher003 mediated functionalization of GVNPs.
CONCLUSION
CONCLUSIONS
The merger of these genetic and chemical functionalization approaches significantly extends these novel protein nanomaterials' bioengineering and functionalization potential to assemble catalytically active proteins, biomaterials, and vaccines onto one nanoparticle in a modular fashion.
Identifiants
pubmed: 36966297
doi: 10.1186/s12951-023-01866-7
pii: 10.1186/s12951-023-01866-7
pmc: PMC10039352
doi:
Substances chimiques
Cysteine
K848JZ4886
Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Informations de copyright
© 2023. The Author(s).
Références
Appl Microbiol Biotechnol. 2013 Nov;97(21):9343-53
pubmed: 24057405
Biotechnol Bioeng. 2001 Sep;76(2):99-107
pubmed: 11505379
Front Microbiol. 2020 Apr 28;11:742
pubmed: 32411108
Microbiology (Reading). 1998 May;144 ( Pt 5):1331-1342
pubmed: 9611808
Biochem J. 1989 Dec 1;264(2):313-22
pubmed: 2513809
Life (Basel). 2022 Sep 19;12(9):
pubmed: 36143491
Science. 1974 Sep 6;185(4154):862-4
pubmed: 4843792
Sci Rep. 2016 Sep 20;6:33679
pubmed: 27646594
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Methods Mol Biol. 2022;2522:33-56
pubmed: 36125742
Microorganisms. 2020 Oct 16;8(10):
pubmed: 33081237
BMC Biol. 2007 May 08;5:17
pubmed: 17488521
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26523-26533
pubmed: 31822621
Mol Microbiol. 1988 Sep;2(5):545-52
pubmed: 3141741
FEBS Open Bio. 2018 Dec 18;9(2):194-205
pubmed: 30761247
Life (Basel). 2015 Feb 02;5(1):385-402
pubmed: 25648404
Methods Mol Biol. 2008;418:73-88
pubmed: 18287651
J Bacteriol. 1994 Dec;176(24):7646-52
pubmed: 8002589
Microbiol Rev. 1994 Mar;58(1):94-144
pubmed: 8177173
Microbiology (Reading). 2020 Jun;166(6):501-509
pubmed: 32324529
ACS Nano. 2016 Aug 23;10(8):7314-22
pubmed: 27351374
ACS Biomater Sci Eng. 2019 Sep 9;5(9):4132-4147
pubmed: 33417774
Biophys J. 2007 Feb 15;92(4):1192-203
pubmed: 17114227
Nat Protoc. 2010 Apr;5(4):725-38
pubmed: 20360767
Mol Microbiol. 2011 Jul;81(1):56-68
pubmed: 21542854
Cytotechnology. 2006 Oct;52(2):139-49
pubmed: 19002872
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Vaccines (Basel). 2015 Sep 07;3(3):686-702
pubmed: 26350601
BMC Bioinformatics. 2008 Jan 23;9:40
pubmed: 18215316
Open Biol. 2020 Dec;10(12):200293
pubmed: 33259746
Bioeng Bugs. 2010 Jul-Aug;1(4):288-90
pubmed: 21327063
BMC Bioinformatics. 2013 Dec 01;14:346
pubmed: 24289175
J Mol Microbiol Biotechnol. 2013;23(4-5):281-9
pubmed: 23920491
Int J Bioprint. 2022 Jun 01;8(3):489
pubmed: 36105129
Appl Microbiol Biotechnol. 2019 May;103(9):3807-3817
pubmed: 30877354
BMC Biotechnol. 2013 Dec 21;13:112
pubmed: 24359319
Sci Rep. 2020 Feb 18;10(1):2802
pubmed: 32071325
Mol Pharm. 2017 Mar 6;14(3):953-958
pubmed: 28068767
J Biotechnol. 2001 Jun 15;88(2):119-28
pubmed: 11403846
Biochemistry. 1982 Dec 21;21(26):6872-9
pubmed: 7159570
Appl Microbiol Biotechnol. 2016 Feb;100(3):1183-1195
pubmed: 26428236
Appl Microbiol Biotechnol. 2022 Mar;106(5-6):2043-2052
pubmed: 35230496
Cell. 2023 Mar 2;186(5):975-986.e13
pubmed: 36868215
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W526-31
pubmed: 15980527
J Nanobiotechnology. 2021 Feb 25;19(1):59
pubmed: 33632278
Nat Chem. 2014 Jul;6(7):629-34
pubmed: 24950334
J Theor Biol. 1966 Nov;12(2):157-95
pubmed: 4291386
Microbiology (Reading). 2001 Apr;147(Pt 4):959-964
pubmed: 11283291
Mol Microbiol. 2017 Nov;106(4):530-542
pubmed: 28898511
Vaccine. 2014 Jul 31;32(35):4543-4549
pubmed: 24950351
ACS Chem Biol. 2018 Jan 19;13(1):161-170
pubmed: 29188989